Altimmune, Inc. Shareholders Encouraged to File for Lead Plaintiff Appointment

Altimmune, Inc. shareholders who purchased shares between August 10, 2023, and June 25, 2025, are advised to contact The Gross Law Firm regarding possible lead plaintiff appointment after the company's announcement of disappointing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide. The stock price plummeted by 53.2% within a single day, from $7.71 to $3.61 per share, following the release of the trial results.

Key Takeaways:

• The Gross Law Firm is seeking recovery on behalf of investors who incurred losses due to the company's alleged false and/or misleading statements or omission of material information that artificially inflated the stock price.
• The class period for this case spans from August 10, 2023, to June 25, 2025.
• The statute of limitations for seeking to be a lead plaintiff is October 6, 2025.
• The Gross Law Firm will provide regular status updates throughout the lifecycle of the case for enrolled shareholders.
• The firm's goal is to ensure that companies engage in good corporate citizenship and adhere to responsible business practices.

Statistics:

• Stock price decline: 53.2% in one day.
• Closing market price before announcement: $7.71 per share.
• Closing market price after announcement: $3.61 per share.
• Duration of the class period: August 10, 2023, to June 25, 2025.

Sources:

• The Gross Law Firm: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form-2/?id=166116&from=3
• Altimmune, Inc. press release (date not specified, but referenced in the text as published on June 26, 2025)